ArticleLipids in health and disease2022
Low lipoprotein(a) concentration is associated with atrial fibrillation: a large retrospective cohort study.
Article in Lipids in health and disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- The association between lipoprotein(a) and atrial fibrillation: A systemic review and meta-analysis.Clinical cardiology · 2023Pooled it
- Distribution of Lipoprotein(a) Levels and Clinical Associations in a Lebanese Adult Population: A Retrospective Observational Study.Journal of clinical medicine · 2026Article
- Circulating lipid profiles and atrial fibrillation: from incident risk to post-ablation recurrence.Frontiers in cardiovascular medicine · 2026Review
- Lipoprotein(a) and Atrial Fibrillation: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2025Review
- Lipoprotein(a) and Atrial Fibrillation: Mechanistic Insights and Therapeutic Approaches.International journal of medical sciences · 2025Review
- The functions of apolipoproteins and lipoproteins in health and disease.Molecular biomedicine · 2024Review
- Role of Lipoprotein(a) Reduction in Cardiovascular Disease.Journal of clinical medicine · 2024Review
- Lipoprotein (a) as a Cardiovascular Risk Factor in Controversial Clinical Scenarios: A Narrative Review.International journal of molecular sciences · 2024Review
- Associations of lipids and lipid-modifying drug target genes with atrial fibrillation risk based on genomic data.Lipids in health and disease · 2024Article
- Plasma triglyceride is associated with the recurrence of atrial fibrillation after radiofrequency catheter ablation: A retrospective study.Clinical cardiology · 2024Article
- High lipoprotein(a) concentration is associated with moyamoya disease.Lipids in health and disease · 2024Article
- The Association of High Lipoprotein(a) Concentration and Risk of Ischaemic Stroke in Atrial Fibrillation Patients.International journal of general medicine · 2024Article
- Lipoprotein(a)-60 Years Later-What Do We Know?Cells · 2023Review
- Elevated Lipoprotein(a) Levels and Atrial Fibrillation: A Systematic Review.Journal of lipid and atherosclerosis · 2023Article
- Correction: Low lipoprotein(a) concentration is associated with atrial fibrillation: A large retrospective cohort study.Lipids in health and disease · 2023Article
- Predictive value of remnant-like particle cholesterol in the prediction of long-term AF recurrence after radiofrequency catheter ablation.Frontiers in cardiovascular medicine · 2023Article
- Lipoprotein(a): Cardiovascular Disease, Aortic Stenosis and New Therapeutic Option.International journal of molecular sciences · 2022Review
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
aimsThe role of serum lipoprotein(a) [Lp(a)] levels in atrial fibrillation (AF) is still uncertain, especially in the Chinese population. Here, we aimed to elucidate the potential relationship between Lp(a) quantiles and AF.
methodsAll data were collected through inpatients with electronic health records from the Second Affiliated Hospital of Nanchang University, Jiangxi Province, China. The propensity score matching (PSM) method was used to match control and case groups. Interactions between AF, Lp(a) quantiles, and other clinical indices were analyzed by logistic regression and stratified analysis. Statistical analyses were performed with IBM SPSS statistical software and R software.
resultsFrom 2017 to 2021, 4,511 patients with AF and 9,022 patients without AF were 1:2 matched by the propensity score matching method. A total of 46.9% of the study group was women, and the baseline mean age was 65 years. The AF group exhibited lower median Lp(a) than the non-AF group (15.95 vs. 16.90 mg/dL; P < 0.001). Based on the Lp(a) quantiles, the study population was divided into four groups: Q1 (≤ 8.71 mg/dL), Q2 (8.71-16.54 mg/dL), Q3 (16.54-32.42 mg/dL) and Q4 (> 32.42 mg/dL). The AF prevalence of each group decreased from 34.2% (Q1) to 30.9% (Q4) (P < 0.001). Lp(a) quantiles 1-3 significantly increased AF to 1.162-fold (1.049-1.286), 1.198-fold (1.083-1.327), and 1.111-fold (1.003-1.231) in the unadjusted logistic regression model, respectively. In the adjusted model, Lp(a) < 32.42 mg/dL still showed a significant inverse association with AF. In the stratified analysis, Lp(a) levels in female patients exhibited a significant negative correlation with AF (OR of Q1: 1.394[1.194-1.626], P = 0.001). Age and hypertension did not affect the adverse correlation.
conclusionLow circulating Lp(a) levels were associated with AF, especially in the female Han population, suggesting that Lp(a) may be useful for risk stratification of AF in female individuals.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.